Feedback PLC TexRAD technology assists in medical trials (7277W)
November 11 2014 - 7:39AM
UK Regulatory
TIDMFDBK
RNS Number : 7277W
Feedback PLC
11 November 2014
11 November 2014
Feedback plc
('Feedback' or "the Company')
TexRAD tumour-imaging technology assists hospitals in assessing
bowel-cancer risk
Feedback plc, the AIM listed medical technology company, is
pleased to announce an update regarding its subsidiary TexRAD Ltd
("TexRAD"). In recent trials, the medical imaging technology
developed by TexRAD, in partnership with the University of Sussex,
has been shown to assist in the early and accurate treatment and
prognosis of patients diagnosed with bowel cancer.
A press release issued by the University of Sussex can be read
in full below:
Tumour-analysis technology enables speedier treatment decisions
for bowel-cancer patients
Technology developed at the University of Sussex helps hospitals
make earlier and more accurate treatment decisions and survival
assessments for patients with bowel cancer.
Bowel cancer kills more than 16,000 people a year in the UK,
making it the nation's second-most common cause of cancer death
(after lung cancer).
A novel medical-imaging technology, TexRAD, which analyses the
texture of tumours, has been shown in trials to enable early
diagnosis of those bowel-cancer patients not responding to the
standard cancer therapy better than other available tumour
markers.
Furthermore, the TexRAD markers showed the ability to assess at
an early stage the likelihood of survival, distinguishing patients
who will have a good prognosis from those having poor
prognosis.
Dr Balaji Ganeshan, one of the Sussex academics whose research
led to the development of the technology, said: "By using TexRAD to
scan for subtle anomalies in a tumour's texture, researchers have
been able to spot more quickly when treatments are - or are not -
working and adjust treatment accordingly.
"And because TexRAD simply provides an additional layer of
software analysis of the MRI and CT scans that already exist as
part of routine clinical practice, it is non-invasive from the
patient's point of view and potentially cost-effective to the
healthcare provider."
The technology is being evaluated in a number of prestigious
research institutions and university hospitals around the
world.
Across two separate UK studies, researchers analysed the tumours
of 155 bowel-cancer patients.
In a study at University College London Hospitals, researchers
analysed baseline PET-CT scans - ie those taken before treatment -
and then followed up with the patients for an average of three
years later. They found that analysing the texture of the tumours
in the initial scans enabled them to accurately predict patient
survival.
At Colchester General Hospital, the researchers looked at MR
scans taken both before treatment and six weeks after the patients
had completed chemotherapy and radiotherapy, and found that the
patients whose tumours were less heterogeneous - ie more uniform -
in terms of texture parameters six weeks after treatment were more
likely to survive longer.
Meanwhile, researchers from the University of Rome found that
texture analysis provides useful 'imaging biomarkers' that indicate
how the tumour is responding to chemotherapy and radiotherapy.
Professor Andrea Laghi, Professor of Radiology at the University of
Rome and principal investigator of the study, said: "The
identification of new, accurate imaging biomarkers such as TexRAD
analysis of MR images for early assessment of first-line cancer
therapy response (predominantly to shrink the tumour before the
main treatment) could be helpful in refining bowel-cancer patient
management, providing a better targeting of preoperative
therapy."
The findings of the three studies will be presented to a wide
international audience of clinicians (radiologists), imaging
scientists, healthcare providers and industry at the 100(th)
premier annual scientific meeting and exhibition of the
Radiological Society of North America (RSNA), which takes place in
Chicago from 30 November until 5 December.
For further information contact:
Feedback plc Tel: 01954 718072
Simon Barrell/Trevor Brown/Tom Charlton
Notes for editors
TexRAD was originally a joint venture between the University of
Sussex, Imaging Equipment Limited, Cambridge Computed Imaging
Limited and Miles Medical Pty Ltd, based on research by Professor
Chris Chatwin, Dr Balaji Ganeshan and Dr Rupert Young from the
Department of Engineering and Design and Brighton and Sussex
Medical School, and Professor Ken Miles. In May 2014, TexRAD Ltd
along with Cambridge Computed Imaging Ltd was bought by Feedback
plc, an AIM-listed company specialising in medical imaging
tools.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAXFLFFZFFXFBD
Feedback (LSE:FDBK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Feedback (LSE:FDBK)
Historical Stock Chart
From Jul 2023 to Jul 2024